Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • Issue Archive
    • Quality Improvement Sucess Stories
    • Recent ADA Position Statements
  • Info
    • About the Journal
    • Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Standards of Medical Care
      • Abridged for Primary Care Providers
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • Issue Archive
    • Quality Improvement Sucess Stories
    • Recent ADA Position Statements
  • Info
    • About the Journal
    • Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
Departments

Basaglar: A Hypersensitivity Reaction

  1. Elizabeth M. Gavioli1,
  2. Roman Fazylov1,2 and
  3. Gulmira Sardo1
  1. 1Kingsbrook Jewish Medical Center, Brooklyn, NY
  2. 2Touro College of Pharmacy, New York, NY
  1. Corresponding author: Elizabeth M. Gavioli, egavioli{at}kingsbrook.org
Clinical Diabetes 2018 Apr; 36(2): 205-207. https://doi.org/10.2337/cd17-0051
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Introduction

The human insulin molecule is composed of a specific sequence of amino acids built in such a way that any change or modification will affect its primary, secondary, or tertiary structure, which in turn can affect the safety and efficacy of the therapeutic protein. As patents on currently available basal insulins begin to expire, biosimilar products will emerge and quickly replace many of these products owing to their favorable pricing profiles. However, biosimilar products are not 100% identical to their reference products because of their complex manufacturing processes from living cells or organisms (1). For that reason, the regulatory requirements for biosmiliars are more complex than for generic molecules. The Biologics Price Competition and Innovation Act of 2009, passed as part of the Patient Protection and Affordable Care Act, allows biosimilar products to be approved by the U.S. Food and Drug Administration (FDA) via an abbreviated pathway (2). Biosimilars must demonstrate no clinically meaningful differences from their reference products in safety, purity, and potency, but they do not have to complete a therapeutic equivalence study. Yet, a major concern with biosimilars is the risk of immunogenicity resulting from variations in manufacturing, and thus clinical studies must be conducted before FDA approval to evaluate potential differences in the incidence and severity of immune responses (3). However, such FDA approval studies may not be sufficient, and post-marketing monitoring of biosimilars is essential for patient safety.

Hypersensitivity reactions to insulin analogs are rare, with only one published case report of a reaction caused by a biosimilar product in China (4). In 2016, Basaglar was the first “follow-on” insulin glargine approved for use in the United States, with an amino acid sequence identical to that of insulin glargine (Lantus) (5). In Europe, this agent is referred to as a “biosimilar,” but because of …

View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top
Clinical Diabetes: 36 (2)

In this Issue

April 2018, 36(2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Clinical Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Basaglar: A Hypersensitivity Reaction
(Your Name) has forwarded a page to you from Clinical Diabetes
(Your Name) thought you would like to see this page from the Clinical Diabetes web site.
Citation Tools
Basaglar: A Hypersensitivity Reaction
Elizabeth M. Gavioli, Roman Fazylov, Gulmira Sardo
Clinical Diabetes Apr 2018, 36 (2) 205-207; DOI: 10.2337/cd17-0051

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Basaglar: A Hypersensitivity Reaction
Elizabeth M. Gavioli, Roman Fazylov, Gulmira Sardo
Clinical Diabetes Apr 2018, 36 (2) 205-207; DOI: 10.2337/cd17-0051
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Introduction
    • Case Presentation
    • Questions
    • Commentary
    • Clinical Pearls
    • Duality of Interest
    • Author Contributions
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Departments

  • Connecting the Dots: An Interdisciplinary Diabetes Quality Improvement Initiative
  • Timely News and Notes for Primary Care Providers From The American Diabetes Association
  • Diabetes Center of Excellence Hypoglycemia Emergency Preparedness Project
Show more 3

Case Studies

  • Delayed Response to U-500 Regular Insulin
  • Drug-Induced Falsely Low A1C: Report of a Case Series From a Diabetes Clinic
Show more 3

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Privacy Notice/Terms of Use
  • Advertising
  • Copyright Notice and Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.